北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第一临床医学院  > 感染疾病科  > 期刊论文
学科主题: 临床医学
题名:
Kinetics and Prediction of HBsAg Loss during Long-Term Therapy with Nucleos(t)ide Analogues of Different Potency in Patients with Chronic Hepatitis B
作者: Li, Min-Ran; Xi, Hong-Li; Wang, Qin-Huan; Hou, Feng-Qin; Huo, Na; Zhang, Xia-Xia; Li, Fang; Xu, Xiao-Yuan
刊名: PLOS ONE
发表日期: 2014-06-06
DOI: 10.1371/journal.pone.0098476
卷: 9, 期:6
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Multidisciplinary Sciences
研究领域[WOS]: Science & Technology - Other Topics
关键词[WOS]: CLOSED CIRCULAR DNA ; SURFACE-ANTIGEN ; LAMIVUDINE THERAPY ; ADEFOVIR DIPIVOXIL ; ANTIVIRAL AGENTS ; NATURAL-HISTORY ; ENTECAVIR ; REDUCTION ; VIRUS ; CCCDNA
英文摘要:

Background & Aims: About 350-400 million people are infected with hepatitis B virus (HBV) chronically and 1 million people die of hepatitis B virus (HBV)-related liver diseases. Nucleos(t)ide analogues (NAs) have been used for the treatment against HBV. However, few studies have investigated the long-term effects of different nucleos(t)ide analogues on levels of hepatitis B surface antigen (HBsAg) in patients with chronic hepatitis B (CHB). The aims of this study were to measure the magnitude of HBsAg reduction by long-term monotherapy with adefovir dipivoxil (ADV) and entecavir (ETV), to compare HBsAg reduction between the two drugs of different potency and to predict the expected time needed to achieve HBsAg loss.

Methods: We retrospectively evaluated the kinetics of HBsAg in 67 patients with CHB who all exhibited persistent viral suppression. These patients were treated with ADV or ETV for at least 6 years. HBV genotype was determined at baseline. Liver biochemistry, HBV serological markers, serum HBV DNA and HBsAg titers were determined at baseline, half year and yearly from year 1 to 6.

Results: Serum HBsAg titers after treatment with ADV or ETV were significantly lower than the baseline titers (P<0.05). HBsAg reduction rate of patients treated with ETV (0.11 log(10) IU/mL/year) was higher than that treated with ADV (0.10 log(10) IU/mL/year), and the calculated expected time to HBsAg loss for patients treated with ETV (approximate 24.99 years) was shorter than that with ADV (approximate 30.33 years), but there was no statistically significant difference between two groups (P>0.05).

Conclusion: Serum HBsAg titers gradually decreased during long-term treatment with either ADV or ETV. It appears that the potency of ADV on HBsAg reduction is close to that of ETV, as long as patients have achieved persistent viral suppression.

语种: 英语
所属项目编号: 2012ZX10002 003-004-003 ; 2013 ZX10002004-001-003 ; D121100003912003
项目资助者: 12th Five-Year Plan ; Beijing Municipal Science and Technology Commission of major projects
WOS记录号: WOS:000341869000033
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/60704
Appears in Collections:北京大学第一临床医学院_感染疾病科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: Peking Univ First Hosp, Dept Infect Dis, Beijing, Peoples R China

Recommended Citation:
Li, Min-Ran,Xi, Hong-Li,Wang, Qin-Huan,et al. Kinetics and Prediction of HBsAg Loss during Long-Term Therapy with Nucleos(t)ide Analogues of Different Potency in Patients with Chronic Hepatitis B[J]. PLOS ONE,2014,9(6).
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Li, Min-Ran]'s Articles
[Xi, Hong-Li]'s Articles
[Wang, Qin-Huan]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Li, Min-Ran]‘s Articles
[Xi, Hong-Li]‘s Articles
[Wang, Qin-Huan]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace